Clinical trial

RW Effectiveness of Lurbinectedin in Extensive Stage SCLC

NCT05285033

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2022-04-01

PhaseN/A

Study timeline

Study start (actual)2022-04-01Date precision: day

Registry last updated2023-01-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small-cell Lung Cancerunresolved

Interventions

LurbinectedinDRUG · verified · RxNorm: lurbinectedin

Sponsors & collaborators

Intergroupe Francophone de Cancerologie Thoraciquelead sponsor

Groupe Francais De Pneumo-Cancerologiecollaborator

PharmaMarcollaborator

Mapped research locations

ParisFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05285033 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.